The primary study endpoint was the mean change in the total MADRS score after 6 weeks of blinded treatment in the non-remitter subset (n=129) of the randomized population, defined as subjects with a total MADRS score of >10 after the 8 week escitalopram treatment. The significance level was prospectively set at 10%.
Vyvanse demonstrated improvement compared to placebo on the mean total MADRS of -2.3 [90% CI -4.5 to -0.1] after 6 weeks of treatment in the primary analysis of non-remitting subjects (p=0.090). An additional pre-planned analysis was conducted among subjects who had a total MADRS score >10 and achieved < 50% improvement in total MADRS score (n=86). This analysis found an endpoint LS mean difference between Vyvanse and placebo of -3.9 [90% CI -6.5 to -1.3; p=0.0132 (not adjusted for multiplicity)]. The most commonly reported adverse events (dry mouth, headache, decreased appetite, and insomnia) in the trial were consistent with the known, labeled profile of VYVANSE in ADHD. Mean blood pressure and mean heart rate changes were also consistent with the product label. No notable mean ECG changes or mean changes in clinical laboratory assessments were reported in this study. The mean dose per day of VYVANSE used for adjunctive therapy with escitalopram was 29.6 mg.
"Only about 30 to 33 percent of patients will achieve full symptom
remission with the first step standard antidepressant treatment," said
Madhukar H. Trivedi, Professor of Psychiatry at University of Texas
Southwestern Medical School. "Therefore, almost two-thirds of patients
starting an antidepressant will need a second or third step treatment to
achieve symptom relief. We are encouraged by the signal findings we've seen
in this Phase 2 study and look forward to further evaluating Vyvanse for
adjunctive treatment of patients w
|SOURCE Shire plc|
Copyright©2010 PR Newswire.
All rights reserved